Percutaneous Hip Denervation for the Treatment of Hip Dysplasia in Dogs
World Small Animal Veterinary Association World Congress Proceedings, 2007
Andre L. Selmi, DVM, MS, PhD; Bianca M. Penteado, DVM; Bruno T. Lins, DVM, MS

Canine hip dysplasia is a common painful orthopedic disorder, progressively incapacitating, resulting from articular instability and causing degenerative joint disease. Several treatment options are available, including capsular denervation. This study describes the results of percutaneous capsular denervation in 92 dogs diagnosed with hip dysplasia. Lameness (LAM) and pain on palpation (PN) were determined using a visual analogue scale (VAS), muscle girth (MG) and maximum degree of passive extension (PME) and flexion (PMF) of the hip were determined pre-operatively and at days 7, 15, 30, 180 and 360 post-operatively. Dogs were anesthetized and an intramedullary pin was used to percutaneously scrap the craniodorsal border of the acetabulum. LAM and PN were analyzed by means of ANOVA followed by a Friedman test, whereas MG, PME and PMF were analyzed by means of ANOVA followed by a Tukey test. There was a significant decrease in LAM and PN 15 days following surgery. PME presented a significant increase after 30 days of surgery. It is concluded that the percutaneous hip denervation is a simple, effective and quick method in restoring function in the dysplastic hip.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

André L. Selmi, DVM, MS, PhD
Universidade Anhembi Morumbi
Sao Paulo, Brazil


MAIN : Abstracts - Poster : Percutaneous Hip Denervation
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27